arrow
S

Steven Abrams

University of Antwerp
H指数:21
被引数:1,757

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Beyond staffing ratios - team demographic diversity, workforce stability, and their effects on patient safety and workforce sustainability: A multi-country analysis (vol 181, 105570, 2026)

超越人员配备比例——团队人口统计多样性、劳动力稳定性及其对病人安全和劳动力可持续性的影响:一项跨国分析(卷181,105570,2026)

2026-08-010
PRE
Decentralizing care for cutaneous leishmaniasis and other skin diseases to primary health facilities in Southern Ethiopia: What are the needs?

将皮肤利什曼病和其他皮肤疾病的护理去中心化至埃塞俄比亚南部的初级卫生保健机构:需求是什么?

2025-12-260
OAAI
An extension of the Benefit Risk Assessment of VaccinEs toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union

对疫苗获益风险评估工具包的扩展,以评估欧盟境内的Comirnaty和Spikevax疫苗接种情况

2025-08-010
OAAI
Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study

利用疫苗效益风险评估(BRAVE)工具包评估Vaxzevria在欧盟的效益与风险:一项基于人群的研究

2025-05-010
OAAI
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
2025-03-060
OAAI
The Intestinal Mucin Isoform Landscape Reveals Region-Specific Biomarker Panels for Inflammatory Bowel Disease Patient Stratification

肠粘蛋白同工型景观揭示了炎症性肠病患者分层的区域特异性生物标志物面板

2024-09-270
OAAI
Characterising information gains and losses when collecting multiple epidemic model outputs
2024-06-012
OA
The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022)

质量调整生命年对评估新型冠状病毒肺炎缓解策略的影响: 比利时特定年龄疫苗接种的经验教训和关注的变体 (2020-2022)

2024-04-263
OAAI
The direct disease burden of COVID-19 in Belgium in 2020 and 2021

比利时新型冠状病毒肺炎的直接疾病负担2020年和2021

2023-09-045
OAAI